Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
February 06, 2020 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it has been notified by The Nasdaq Stock Market LLC that the...
Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference
February 05, 2020 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
January 30, 2020 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it was notified by the Nasdaq Office of General Counsel that...
Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update
January 15, 2020 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study
December 18, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared...
Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
December 11, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based...
Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems
December 10, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will give one of the feature presentations at the...
Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform
November 21, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARÉ), a leader in women’s health innovation, today announced the closing of the previously announced acquisition by merger...
Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update
November 14, 2019 08:00 ET
|
Dare Bioscience, Inc.
SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2019...
Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate
November 12, 2019 08:00 ET
|
Dare Bioscience, Inc.
Across all women and all cycles evaluated, Ovaprene prevented essentially all sperm from entering the cervical canal, a surrogate marker for contraceptive effectiveness.Currently marketed...